Gonadotropin-releasing hormone (GnRH) agonists, currently used in the treatment of advanced prostate cancer, have been described as a rare cause of pituitary apoplexy, a potentially life-threatening clinical condition. We report the case of a 69-year-old man with a known pituitary macroadenoma who was diagnosed with prostate cancer and started treatment with GnRH agonist leuprorelin (other hormones were not tested before treatment). Few minutes after drug administration, the patient presented with acute-onset severe headache, followed by left eye ptosis, diplopia and vomiting. Pituitary MRI revealed tumor enlargement and T1-hyperintense signal, compatible with recent bleeding sellar content. Laboratory endocrine workup was significant for low total testosterone. The patient was managed conservatively with high-dose steroids, and symptoms significantly improved. This case describes a rare phenomenon, pituitary apoplexy induced by GnRH agonist. We review the literature regarding this condition: the pathophysiological mechanism involved is not clearly established and several hypotheses have been proposed. Although uncommon, healthcare professionals and patients should be aware of this complication and recognize the signs, preventing a delay in diagnosis and treatment.

Learning points:

Pituitary apoplexy (PA) is a potentially life-threatening complication that can be caused by gonadotropin-releasing hormone agonist (GnRHa) administration for the treatment of advanced prostate cancer.
This complication is rare but should be taken into account when using GnRHa, particularly in the setting of a known pre-existing pituitary adenoma.
PA presents with classic clinical signs and symptoms that should be promptly recognized.
Patients should be instructed to seek medical care if suspicious symptoms occur.
Healthcare professionals should be aware of this complication, enabling its early recognition, adequate treatment and favorable outcome.

Patient Demographics: Adult, Male, White, Portugal

Clinical Overview: Pituitary, Pituitary, GNRH, Testosterone, Pituitary adenoma, Pituitary apoplexy, Prostate cancer

Diagnosis and Treatment: Headache, Diplopia, Ptosis, Vomiting, MRI, Testosterone, CT scan, TSH, Prolactin, Cortisol, C-reactive protein, Radiotherapy, Leuprolide acetate , Steroids, Dexamethasone, Glucocorticoids, Methylprednisolone, Hydrocortisone

Related Disciplines: Urology

Publication Details: Unusual effects of medical treatment, June, 2020

Abstract

References

1. Rajasekaran S, Vanderpump M, Baldeweg S, Drake W, Reddy N, Lanyon M, Markey A, Plant G, Powell M, Sinha S, et alUK guidelines for the management of pituitary apoplexy. Clinical Endocrinology 2011. 74 9–20. (10.1111/j.1365-2265.2010.03913.x) [] [[PubMed]
2. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higanoet CS, et alProstate cancer, version 2.2019, NCCN Clinical Practice Guidelines in oncology. Journal of the National Comprehensive Cancer Network 2019. 17 479–505. (10.6004/jnccn.2019.0023) [] [[PubMed]
3. Tanios G, Mungo NA, Kapila A, Bajaj K. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment. BMJ Case Reports 2017. (10.1136/bcr-2016-218514) ] [
4. Spengos K, Pavlopoulos C, Grivas A. Pituitary haemorrhage after leuprolide therapy for prostatic cancer, clinically imitating acute subarachnoidal haemorrhage. Cerebrovascular Diseases 2002. 14 272 (10.1159/000065664) [] [[PubMed]
5. Sinnadurai M, Cherukuri RK, Moses RG, Nasser E. Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists. Journal of Clinical Neuroscience 2010. 17 1201–1203. (10.1016/j.jocn.2010.01.012) [] [[PubMed]
6. Ito Y. Unexpected enlargement of clinically silent pituitary gonadotroph adenoma induced by goserelin acetate given as treatment for prostate cancer. International Journal of Urology 2011. 18 83–84. (10.1111/j.1442-2042.2010.02676.x) [] [[PubMed]
7. Babbo A, Kalapurakal GT, Liu B, Bajramovic S, Chandler JP, Garnett J, Kalapurakal JA. The presence of a pituitary tumor in patients with prostate cancer is not a contraindication for leuprolide therapy. International Urology and Nephrology 2014. 46 1775–1778. (10.1007/s11255-014-0708-z) [] [[PubMed]
8. Guerrero-Pérez F, Marengo AP, Planas-Vilaseca A, Flores-Escobar V, Villabona-Artero C. Pituitary apoplexy induced by triptorelin in patient with prostate cancer. Endocrinologia y Nutricion 2015. 62 411–412. (10.1016/j.endonu.2015.05.005) [] [[PubMed]
9. Huang TY, Lin JP, Lieu AS, Chen YT, Chen HS, Jang MY, Shen JT, Wu WJ, Huang SP, Juan YS. Pituitary apoplexy induced by gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case. World Journal of Surgical Oncology 2013. 11 254 (10.1186/1477-7819-11-254) ] [
10. Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary 2010. 13 54–59. (10.1007/s11102-009-0202-2) [] [[PubMed]
11. Ando S, Hoshino T, Mihara S. Pituitary apoplexy after goserelin. Lancet 1995. 345 458 (10.1016/s0140-6736(95)90443-3) [] [[PubMed]
12. Chanson P, Schaison G. Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma. Journal of Clinical Endocrinology & Metabolism 1995. 80 2267–2278. (10.1210/jcem.80.7.7608291) [] [[PubMed]
13. Morsi A, Jamal S, Silverberg JD. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clinical Endocrinology 1996. 44 121–124. (10.1046/j.1365-2265.1996.644465.x) [] [[PubMed]
14. Reznik Y, Chapon F, Lahlou N, Deboucher N, Mahoudeau J. Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer. Journal of Endocrinological Investigation 1997. 20 566–568. (10.1007/BF03348020) [] [[PubMed]
15. Eaton HJ, Phillips PJ, Hanieh A, Cooper J, Bolt J, Torpy DJ. Rapid onset of pituitary apoplexy after goserelin implant for prostate cancer: need for heightened awareness. Internal Medicine Journal 2001. 31 313–314. (10.1046/j.1445-5994.2001.00065.x) [] [[PubMed]
16. Hernandez Morin N, Huet D, Hautecouverture M. Two cases of non-functional gonadotroph adenoma pituitary apoplexy following GnRH-agonist treatment revealing gonadotroph adenoma and pseudopituitary apoplexy after GnRH administration. Annals of Endocrinology 2003. 64 227–231. [[PubMed]
17. Błaut K, Wiśniewski P, Syrenicz A, Sworczak K. Apoplexy of clinically silent pituitary adenoma during prostate Cancer treatment with LHRH analog. Neuro Endocrinology Letters 2006. 27 569–572. [[PubMed]
18. Davis A, Goel S, Picolos M, Wang M & Lavis V. Pituitary apoplexy after leuprolide. Pituitary 2006. 9 263–265. (10.1007/s11102-006-8616-6) [] [[PubMed][Google Scholar]
19. Massoud W, Paparel P, Lopez J-G, Perrin P, Daumont M, Ruffion A. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. International Journal of Urology 2006. 13 87–88. (10.1111/j.1365-2265.2010.03913.x) [] [[PubMed]
20. Hands KE, Alvarez A, Bruder J M. Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature. Endocrine Practice 2007. 13 642–646. (10.4158/EP.13.6.642) [] [[PubMed]
21. Sasagawa Y, Tachibana O, Nakagawa A, Koya D, Iizuka H. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma. Journal of Clinical Neuroscience 2015. 22 601–603 (10.1016/j.jocn.2014.08.015) [] [[PubMed]
22. Keane F, Egan A M, Navin P, Brett F, Dennedy MC. Gonadotropin-releasing hormone agonist-induced pituitary apoplexy. Endocrinology, Diabetes & Metabolism Case Reports 2016. 2016 160021 (10.1530/EDM-16-0021) ] [
23. Fabiano AJ, George S. Pituitary apoplexy after Initial Leuprolide injection. World Neurosurgery 2016. 95 616.e7–616.e9. (10.1016/j.wneu.2016.08.091) [] [[PubMed]